<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1333" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1333/" /><meta name="ncbi_pagename" content="Spinal and Bulbar Muscular Atrophy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Spinal and Bulbar Muscular Atrophy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Spinal and Bulbar Muscular Atrophy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/01/26" /><meta name="citation_author" content="Albert La Spada" /><meta name="citation_pmid" content="20301508" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1333/" /><meta name="citation_keywords" content="Kennedy's Disease" /><meta name="citation_keywords" content="SBMA" /><meta name="citation_keywords" content="X-Linked Spinal and Bulbar Muscular Atrophy" /><meta name="citation_keywords" content="Kennedy's Disease" /><meta name="citation_keywords" content="SBMA" /><meta name="citation_keywords" content="X-Linked Spinal and Bulbar Muscular Atrophy" /><meta name="citation_keywords" content="Androgen receptor" /><meta name="citation_keywords" content="AR" /><meta name="citation_keywords" content="Spinal and Bulbar Muscular Atrophy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Spinal and Bulbar Muscular Atrophy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Albert La Spada" /><meta name="DC.Date" content="2017/01/26" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1333/" /><meta name="description" content="Spinal and bulbar muscular atrophy (SBMA) is a gradually progressive neuromuscular disorder in which degeneration of lower motor neurons results in muscle weakness, muscle atrophy, and fasciculations. SBMA occurs only in males. Affected individuals often show gynecomastia, testicular atrophy, and reduced fertility as a result of mild androgen insensitivity." /><meta name="og:title" content="Spinal and Bulbar Muscular Atrophy" /><meta name="og:type" content="book" /><meta name="og:description" content="Spinal and bulbar muscular atrophy (SBMA) is a gradually progressive neuromuscular disorder in which degeneration of lower motor neurons results in muscle weakness, muscle atrophy, and fasciculations. SBMA occurs only in males. Affected individuals often show gynecomastia, testicular atrophy, and reduced fertility as a result of mild androgen insensitivity." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1333/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/kennedy/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1333/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C95E7E040AE210000000001230069.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1333_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1333_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/spg11/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sma/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1333_"><span class="title" itemprop="name">Spinal and Bulbar Muscular Atrophy</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Kennedy's Disease, SBMA, X-Linked Spinal and Bulbar Muscular Atrophy</div><p class="contrib-group"><span itemprop="author">Albert La Spada</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1333_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1333_ai__"><div class="contrib half_rhythm"><span itemprop="author">Albert La Spada</span>, MD, PhD<div class="affiliation small">University of California San Diego School of Medicine<br />La Jolla, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.dscu@adapsala" class="oemail">ude.dscu@adapsala</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 26, 1999</span>; Last Update: <span itemprop="dateModified">January 26, 2017</span>.</p><p><em>Estimated reading time: 21 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="kennedy.Summary" itemprop="description"><h2 id="_kennedy_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Spinal and bulbar muscular atrophy (SBMA) is a gradually progressive neuromuscular disorder in which degeneration of lower motor neurons results in muscle weakness, muscle atrophy, and fasciculations. SBMA occurs only in males. Affected individuals often show gynecomastia, testicular atrophy, and reduced fertility as a result of mild androgen insensitivity.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of SBMA is established in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by the identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> expansion of a CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> (&#x0003e;35 CAGs) in <i>AR</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Use of braces and walkers for ambulation as needed as the disease progresses; breast reduction surgery for gynecomastia as needed.</p><p><i>Surveillance:</i> Annual assessment of strength; annual assessment of pulmonary function in advanced cases.</p><p><i>Other:</i> Clinical trials of anti-androgen drugs (e.g., leuprorelin) did not reveal significant efficacy. Based on animal studies, administration of testosterone and its analogs may make the motor neuron disease worse.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>SBMA is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. Affected males who are fertile pass the expanded CAG repeat to each daughter. Carrier females have a 50% chance of transmitting the CAG trinucleotide expansion to each child; males who inherit it will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit it will be carriers and will not be affected. Carrier testing for at-risk female relatives and prenatal testing for pregnancies at increased risk are possible if the expanded CAG repeat has been identified in an affected family member.</p></div></div><div id="kennedy.Diagnosis"><h2 id="_kennedy_Diagnosis_">Diagnosis</h2><div id="kennedy.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Spinal and bulbar muscular atrophy (SBMA) <b>should be suspected</b> in males with the following clinical features and family history.</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div>Adolescent-onset signs of androgen insensitivity (e.g., gynecomastia)</div></li><li class="half_rhythm"><div>Post-adolescent onset of:</div><ul><li class="half_rhythm"><div>Spinal lower motor neuron disease with muscle weakness of the limbs or muscle cramps</div></li><li class="half_rhythm"><div>Bulbar lower motor neuron disease with fasciculations of the tongue, lips, or perioral region; dysarthria and difficulty swallowing</div></li></ul></li><li class="half_rhythm"><div>No signs of upper motor neuron disease (e.g., hyperreflexia, spasticity)</div></li></ul><p><b>Family history</b> consistent with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance</p><p>Note: Lack of a family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance does not preclude the diagnosis.</p></div><div id="kennedy.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of SBMA <b>is established</b> in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by the identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> expansion of a CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> (&#x0003e;35 CAGs) in <i>AR</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1333/table/kennedy.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figkennedyTmoleculargenetictestingused" rid-ob="figobkennedyTmoleculargenetictestingused">Table 1</a>).</p><p><b>Allele sizes.</b> All individuals with SBMA have an expansion in the number of CAG trinucleotide repeats in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1 of <i>AR</i>.</p><ul><li class="half_rhythm"><div><b>Normal alleles.</b> 34 or fewer CAG trinucleotide repeats</div></li><li class="half_rhythm"><div><b>Mutable normal alleles.</b> None reported to date</div></li><li class="half_rhythm"><div><b>Reduced-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> alleles.</b>
<a class="bk_pop" href="#kennedy.REF.kuhlenb_umer.2001.23">Kuhlenb&#x000e4;umer et al [2001]</a> suggested that an <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> of 37 CAG trinucleotide repeats can manifest reduced penetrance. Therefore, the clinical significance of alleles with 36-37 CAG repeats should be interpreted within the context of family history, the consultand's clinical presentation, and <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> in other family members.</div></li><li class="half_rhythm"><div><b>Full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> alleles.</b> 38 or more CAG trinucleotide repeats</div></li><li class="half_rhythm"><div><b>Alleles of questionable significance.</b> There is no consensus as to the clinical significance of alleles of 35 CAG repeats. Interpretation of alleles of this size may require consideration of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's clinical presentation and reconciliation with repeat sizes in family members.</div></li></ul><p>Molecular genetic testing approaches include <b>targeted testing</b> for the CAG repeat size in <i>AR</i>.</p><div id="kennedy.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Spinal and Bulbar Muscular Atrophy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1333/table/kennedy.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__kennedy.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_kennedy.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_kennedy.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_kennedy.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_kennedy.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>AR</i></td><td headers="hd_h_kennedy.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_kennedy.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="kennedy.TF.1.1"><p class="no_margin">See <a href="/books/NBK1333/#kennedy.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="kennedy.TF.1.2"><p class="no_margin">See <a href="#kennedy.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="kennedy.TF.1.3"><p class="no_margin">CAG repeat number can be determined by fragment length analysis of amplicons from <a class="def" href="/books/n/gene/glossary/def-item/polymerase-chain-reaction/">polymerase chain reaction</a> (<a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>) amplification of the CAG repeat region within AR.</p></div></dd></dl></div></div></div></div></div><div id="kennedy.Clinical_Characteristics"><h2 id="_kennedy_Clinical_Characteristics_">Clinical Characteristics</h2><div id="kennedy.Clinical_Description"><h3>Clinical Description</h3><p>Spinal and bulbar muscular atrophy (SBMA, or Kennedy's disease, named for the neurologist who published an early clinical description) is a disorder of slowly progressive muscle weakness associated with mild androgen insensitivity [<a class="bk_pop" href="#kennedy.REF.kennedy.1968.671">Kennedy et al 1968</a>, <a class="bk_pop" href="#kennedy.REF.harding.1982.1012">Harding et al 1982</a>]. Only males are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><p><b>Neurologic findings.</b> Neurologic symptoms typically begin between age 30 and 50 years [<a class="bk_pop" href="#kennedy.REF.atsuta.2006.1446">Atsuta et al 2006</a>, <a class="bk_pop" href="#kennedy.REF.rhodes.2009.3242">Rhodes et al 2009</a>]. Onset of neurologic symptoms does not usually occur in childhood or adolescence.</p><p>Early signs are difficulty with walking and a tendency to fall. Many individuals have muscle cramps, while others complain of an action tremor [<a class="bk_pop" href="#kennedy.REF.grunseich.2014b.6">Grunseich et al 2014b</a>]. Deep tendon reflexes are decreased.</p><p>After one to two decades of symptoms, most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have difficulty climbing stairs. With time, atrophy of the proximal and distal musculature becomes evident. About one third of affected individuals require a wheelchair 20 years after the onset of symptoms.</p><p>Most individuals eventually show involvement of the bulbar muscles and have difficulty with speech articulation and swallowing. Severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals (many of whom are nonambulatory) are at risk for aspiration pneumonia and ventilatory failure because of weakness of the bulbar and respiratory musculature [<a class="bk_pop" href="#kennedy.REF.mariotti.2000.391">Mariotti et al 2000</a>, <a class="bk_pop" href="#kennedy.REF.atsuta.2006.1446">Atsuta et al 2006</a>]. This complication is the main life-threatening problem in SBMA, and likely becomes an issue for only a minority of individuals. Therefore, the majority of individuals with SBMA have a normal life expectancy and do not die from direct complications of their motor neuron disease. Fifteen of 223 persons in the <a class="bk_pop" href="#kennedy.REF.atsuta.2006.1446">Atsuta et al [2006]</a> study died at a mean age of 65 years.</p><p>Affected males may also have degeneration of the dorsal root ganglia, leading to mild (usually subclinical) abnormalities in sensory function in the distal extremities [<a class="bk_pop" href="#kennedy.REF.antonini.2000.252">Antonini et al 2000</a>, <a class="bk_pop" href="#kennedy.REF.grunseich.2014b.6">Grunseich et al 2014b</a>].</p><p><b>Electrodiagnostic studies</b> are consistent with diffuse denervation atrophy, anterior horn cell loss, and sensory neuronopathy [<a class="bk_pop" href="#kennedy.REF.olney.1991.823">Olney et al 1991</a>, <a class="bk_pop" href="#kennedy.REF.ferrante.1997.323">Ferrante &#x00026; Wilbourn 1997</a>].</p><p><b>Histopathology.</b> Degeneration of anterior horn cells in the spinal cord of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals is observed [<a class="bk_pop" href="#kennedy.REF.kennedy.1968.671">Kennedy et al 1968</a>, <a class="bk_pop" href="#kennedy.REF.amato.1993.791">Amato et al 1993</a>, <a class="bk_pop" href="#kennedy.REF.ogata.1994.1274">Ogata et al 1994</a>]. Changes in muscle include evidence of myopathy [<a class="bk_pop" href="#kennedy.REF.sorar_.2008.100">Sorar&#x000f9; et al 2008</a>], in addition to neurogenic muscle atrophy. Immunohistochemistry shows inclusions of mutated androgen receptor (AR) protein [<a class="bk_pop" href="#kennedy.REF.adachi.2005.659">Adachi et al 2005</a>].</p><p><b>Androgen insensitivity.</b> Symptoms of androgen insensitivity typically begin in adolescence with gynecomastia, which is observed frequently in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males [<a class="bk_pop" href="#kennedy.REF.warner.1992.2181">Warner et al 1992</a>, <a class="bk_pop" href="#kennedy.REF.sinnreich.2004.378">Sinnreich et al 2004</a>]. Variability in disease severity and progression occurs both within and between families [<a class="bk_pop" href="#kennedy.REF.la_spada.1992.301">La Spada et al 1992</a>, <a class="bk_pop" href="#kennedy.REF.doyu.1993.832">Doyu et al 1993</a>, <a class="bk_pop" href="#kennedy.REF.lee.2005.57">Lee et al 2005</a>]. This is especially true of the androgen insensitivity signs of testicular atrophy and oligospermia/azoospermia with reduced fertility (see <a href="/books/n/gene/androgen/">Androgen Insensitivity Syndrome</a>). Males with SBMA may not be able to grow a thick beard and may have difficulty conceiving.</p><p>The androgen insensitivity can be of greater concern to <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals than the motor neuron disease, especially early in the course of the disorder [<a class="bk_pop" href="#kennedy.REF.warner.1992.2181">Warner et al 1992</a>].</p><div id="kennedy.Heterozygotes"><h4>Heterozygotes</h4><p><b>Neurologic findings.</b> Females who are carriers of full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> alleles of greater than 38 CAG repeats in <i>AR</i> are usually asymptomatic. While number of carriers have experienced muscle cramps or occasional tremors, female carriers usually do not have significant motor neuron disease [<a class="bk_pop" href="#kennedy.REF.nance.1997.881">Nance 1997</a>, <a class="bk_pop" href="#kennedy.REF.mariotti.2000.391">Mariotti et al 2000</a>].</p><p>Females who are symptomatic may have an abnormal electromyography [<a class="bk_pop" href="#kennedy.REF.sobue.1993.74">Sobue et al 1993</a>].</p><p><b>Androgen insensitivity.</b> SBMA is a sex-limited disorder, with females protected by having low levels of circulating androgens leading to lower levels of androgen receptor stimulation. In addition, due to <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>, females have only a portion of actively transcribed full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> alleles (CAG&#x0003e;37), but it is the low level of circulating androgen that likely accounts for limited to absent symptoms in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female carriers or in females with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> full-penetrance <i>AR</i> alleles.</p></div></div><div id="kennedy.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Studies of the number of CAG repeats in <i>AR</i> alleles in males with SBMA have established a correlation between number of CAG repeats and disease severity. In general, CAG repeat number inversely correlates with the age of onset of muscle weakness, difficulty climbing stairs, and wheelchair dependence [<a class="bk_pop" href="#kennedy.REF.la_spada.1992.301">La Spada et al 1992</a>]. Thus, males with SBMA whose alleles have a larger number of CAG repeats tend to have earlier disease onset and more rapid progression [<a class="bk_pop" href="#kennedy.REF.doyu.1992.707">Doyu et al 1992</a>, <a class="bk_pop" href="#kennedy.REF.igarashi.1992.2300">Igarashi et al 1992</a>]. For example, early onset (age 8-15 years) and rapid progression have been described in a family in which <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have alleles of 50-54 CAG repeats [<a class="bk_pop" href="#kennedy.REF.echanizlaguna.2005.1458">Echaniz-Laguna et al 2005</a>].</p><p>However, these correlations are only generalizations and exceptions have been reported. For example, a male in a family with SBMA with <i>AR</i> alleles of 37 CAG repeats (the average number of repeats in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males) has been reported to be asymptomatic at age 46 years [<a class="bk_pop" href="#kennedy.REF.kuhlenb_umer.2001.23">Kuhlenb&#x000e4;umer et al 2001</a>]. The largest <i>AR</i> repeat expansion reported in a person with SBMA is 68 [<a class="bk_pop" href="#kennedy.REF.grunseich.2014a.978">Grunseich et al 2014a</a>].</p><p>The <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation between allelic CAG repeat number and disease severity can only account for about 60% of the variability observed in clinical findings, indicating that other factors in addition to CAG repeat number determine age of disease onset and rate of disease progression. Indeed, relatives with SBMA with an identical CAG repeat number may have considerably different disease courses.</p></div><div id="kennedy.Nomenclature"><h3>Nomenclature</h3><p>In the past, SBMA has been called <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> spinal muscular atrophy.</p></div><div id="kennedy.Prevalence"><h3>Prevalence</h3><p>SBMA has an estimated prevalence of 1:300,000 males. It only occurs in individuals of European or Asian racial background; it has yet to be reported in individuals of African or aboriginal racial background.</p><p>European populations in which SBMA has been observed include English, Belgian, French, Italian, German, Polish, Spanish, Swiss, Moroccan, and Turkish [<a class="bk_pop" href="#kennedy.REF.la_spada.1991.77">La Spada et al 1991</a>]. A <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a> has been reported in Scandinavia [<a class="bk_pop" href="#kennedy.REF.lund.2000.631">Lund et al 2000</a>].</p><p>Asian populations in which SBMA has been observed include Chinese, Japanese, Korean, and Vietnamese. SBMA is much more common in the Japanese population than in other ethnic groups because of a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a> [<a class="bk_pop" href="#kennedy.REF.tanaka.1996.1253">Tanaka et al 1996</a>].</p></div></div><div id="kennedy.Genetically_Related_Allelic_Diso"><h2 id="_kennedy_Genetically_Related_Allelic_Diso_">Genetically Related (Allelic) Disorders</h2><p>Other pathogenic variants in <i>AR</i> cause <a href="/books/n/gene/androgen/">androgen insensitivity syndrome</a>.</p></div><div id="kennedy.Differential_Diagnosis"><h2 id="_kennedy_Differential_Diagnosis_">Differential Diagnosis</h2><p>A number of hereditary and acquired neuromuscular disorders can produce gradually progressive muscle weakness.</p><p>The disorder with which spinal and bulbar muscular atrophy (SBMA) is most often confused is <a href="/books/n/gene/als-overview/">amyotrophic lateral sclerosis</a> (ALS). Probably about one in 25 individuals diagnosed with ALS actually has SBMA instead of ALS [<a class="bk_pop" href="#kennedy.REF.parboosingh.1997.568">Parboosingh et al 1997</a>]. Differentiation of ALS from SBMA can usually be made based on history and physical examination. ALS involves upper as well as lower motor neurons; individuals with ALS usually display upper motor neuron signs including hyperreflexia and spasticity. Individuals with ALS typically show involvement of a wider range of muscle groups as well as a more rapid disease progression. An important feature of SBMA is androgen insensitivity, which often causes gynecomastia; thus evaluation of males with motor neuron disease should include an assessment of breast size to determine if gynecomastia is present [<a class="bk_pop" href="#kennedy.REF.nagashima.1988.141">Nagashima et al 1988</a>].</p><p>Other forms of spinal muscular atrophy (SMA) that show <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>, and even <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance have been described [<a class="bk_pop" href="#kennedy.REF.zerres.1989.85">Zerres 1989</a>]. Of these, autosomal recessive <a href="/books/n/gene/sma/">SMA</a> is the most common, occurring as five different phenotypes based on age of onset and maximum function attained. Types 0-III are known respectively as <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> SMA, Werdnig-Hoffman disease (acute), Dubowitz disease (chronic), and Kugelberg-Welander disease; all four types present in infancy or childhood, allowing clear differentiation from SBMA. Type IV SMA, like SBMA, has adult onset, but is much rarer than types 0-III.</p><p>Muscle atrophy and muscle weakness from loss of motor neurons in the spinal cord are seen in other inherited neurodegenerative disorders including <a href="/books/n/gene/sca3/">spinocerebellar ataxia type 3</a> (SCA3 or Machado-Joseph disease), <a href="/books/n/gene/friedreich/">Friedreich ataxia</a> (FRDA), <a href="/books/n/gene/tay-sachs/">Tay-Sachs disease</a>, and the adrenomyeloneuropathy (AMN) variant of <a href="/books/n/gene/x-ald/">X-linked adrenoleukodystrophy</a> (X-ALD); however, these disorders are quite different from SBMA. Individuals with prominent sensory findings in addition to muscle weakness could have a peripheral neuropathy (see <a href="/books/n/gene/cmt/">Charcot-Marie-Tooth Hereditary Neuropathy Overview</a>).</p><p>Non-genetic causes for motor neuron disease include structural lesions (e.g., spinal cord arteriovenous malformations), infections (especially poliomyelitis), toxins (chronic lead poisoning), metabolic problems (thyrotoxicosis), and paraneoplastic syndromes. Individuals with SBMA have been misdiagnosed as having chronic inflammatory neuropathy, metabolic myopathy, polymyositis, and myasthenia gravis.</p></div><div id="kennedy.Management"><h2 id="_kennedy_Management_">Management</h2><div id="kennedy.Evaluations_Following_Initial_Di"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with spinal and bulbar muscular atrophy (SBMA), the following are recommended:</p><ul><li class="half_rhythm"><div>Assessment of/for:</div><ul><li class="half_rhythm"><div>Neurologic findings; attention to distal muscle strength and deep tendon reflexes</div></li><li class="half_rhythm"><div>Speech</div></li><li class="half_rhythm"><div>Swallowing</div></li><li class="half_rhythm"><div>Androgen responsiveness: male pattern hair growth, testicular size, and fertility</div></li><li class="half_rhythm"><div>Gynecomastia</div></li></ul></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="kennedy.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Physical therapy and rehabilitation approaches, including the use of braces and walkers, offer the best prospect for remaining ambulatory as the disease progresses.</p><p>Some individuals with SBMA have breast reduction surgery for gynecomastia [<a class="bk_pop" href="#kennedy.REF.sperfeld.2002.1921">Sperfeld et al 2002</a>].</p></div><div id="kennedy.Prevention_of_Primary_Manifestat"><h3>Prevention of Primary Manifestations</h3><p>There are currently no effective treatments to prevent development of disease manifestations in an asymptomatic individual known to possess an expanded CAG repeat after presymptomatic diagnosis.</p></div><div id="kennedy.Prevention_of_Secondary_Complica"><h3>Prevention of Secondary Complications</h3><p>The most worrisome complications in SBMA result from bulbar weakness, as these complications (asphyxiation and aspiration pneumonia) can be life threatening. Individuals with bulbar weakness must be counseled in the importance of carefully cutting their food into small pieces for eating and avoiding items that may be difficult to chew and then swallow.</p></div><div id="kennedy.Surveillance"><h3>Surveillance</h3><p>Appropriate measures include:</p><ul><li class="half_rhythm"><div>Strength testing (annually)</div></li><li class="half_rhythm"><div>Pulmonary function tests (annually in advanced cases)</div></li></ul></div><div id="kennedy.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Individuals with a tendency to fall should avoid slippery or rough walking surfaces.</p></div><div id="kennedy.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#kennedy.Related_Genetic_Counseling_Issue">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="kennedy.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p><b>High-dose testosterone.</b> At least one clinical trial of high-dose oral testosterone has been undertaken; no significant benefit was derived for the androgen treatment group [<a class="bk_pop" href="#kennedy.REF.goldenberg.1996.158">Goldenberg &#x00026; Bradley 1996</a>]. Based on research in <i>Drosophila</i> and mouse models of SBMA, many investigators believe that androgen treatment can be harmful.</p><p><b>Anti-androgen therapy.</b> There is no consensus or clear evidence as to whether anti-androgen therapy is an effective form of treatment for the neurologic complications.</p><ul><li class="half_rhythm"><div>Anti-androgen therapy shows promise based on studies in <i>Drosophila</i> and mouse models as well as knowledge of the molecular basis of SBMA. For these reasons, a Japanese group [<a class="bk_pop" href="#kennedy.REF.banno.2009.140">Banno et al 2009</a>] performed a clinical trial of leuprorelin in individuals with SBMA who were followed over 48 weeks: significant improvement was observed in cricopharyngeal opening duration, but in no other outcome measures. In particular, there was no effect on the primary outcome measure (the ALS Functional Rating Scale or ALSFRS) in the period of randomization. Although the trial was continued as an open label extension, and encouraging results were reported, the conclusion was that this clinical trial did not establish efficacy for anti-androgen therapy in SBMA [<a class="bk_pop" href="#kennedy.REF.fischbeck.2009.119">Fischbeck &#x00026; Bryan 2009</a>].</div></li><li class="half_rhythm"><div>A larger subsequent study with swallow function as the primary outcome measure also did not show an overall benefit, except in post hoc analysis of subjects in whom disease duration was less than ten years [<a class="bk_pop" href="#kennedy.REF.katsuno.2010.875">Katsuno et al 2010</a>].</div></li><li class="half_rhythm"><div>Another anti-androgen therapy approach was attempted [<a class="bk_pop" href="#kennedy.REF.fern_ndezrhodes.2011.140">Fern&#x000e1;ndez-Rhodes et al 2011</a>]: individuals with SBMA were randomized to placebo or dutasteride, a drug that blocks the conversion of testosterone to dihydrotestosterone (DHT). The rationale was that DHT may mediate many of the toxic effects, and this drug would permit <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals to retain the anabolic effects of testosterone, thereby diminishing the side effects of anti-androgen therapy. However, this study did not show a significant effect of dutasteride on the progression of muscle weakness in SBMA.</div></li></ul><p>Hence, the utility of anti-androgen therapy as a treatment for SBMA remains unclear. Furthermore, it is possible that anti-androgen therapies, even if effective, would need to be administered prior to disease onset or early on in the neurodegenerative process. More importantly, the side effects of anti-androgen therapies would probably far outweigh the therapeutic benefit for most individuals, and likely should be reserved for people with SBMA who are wheelchair bound or exhibit pronounced bulbar weakness.</p><p><b>Creatine supplementation.</b> Studies of <a href="/books/n/gene/als-overview/">amyotrophic lateral sclerosis</a> (ALS) suggest that creatine supplementation may temporarily enhance muscle strength and exercise performance in this motor neuron disease [<a class="bk_pop" href="#kennedy.REF.mazzini.2001.139">Mazzini et al 2001</a>], prompting speculation that it may offer a similar benefit to individuals with SBMA; this remains to be tested.</p><p><b>Experimental therapies in animal models</b></p><ul><li class="half_rhythm"><div>Other interventions that have been shown to have benefit in mouse models of SBMA include the HSP-90 inhibitors 17-AAG and 17-DMAG, the synthetic curcumin derivative ASC-J9, and insulin-like growth factor 1 (reviewed in <a class="bk_pop" href="#kennedy.REF.fischbeck.2012.257">Fischbeck [2012]</a>).</div></li><li class="half_rhythm"><div>More recently, one group directly examined the role of muscle expression of mutated AR in SBMA disease pathogenesis by developing a BAC transgenic mouse model featuring a floxed first <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> to permit cell-type specific excision of a human <i>AR</i> transgene [<a class="bk_pop" href="#kennedy.REF.cortes.2014.295">Cortes et al 2014</a>]. They engineered the human <i>AR</i> transgene to carry 121 CAG repeats (BAC fxAR121), and found that BAC fxAR121 mice develop a gender-restricted, progressive neuromuscular <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, characterized by weight loss, motor deficits, muscle atrophy, myopathy, and shortened life span. By terminating expression of mutated AR in the skeletal muscles of BAC fxAR121 male mice, this study revealed a crucial role for muscle expression of mutated AR in SBMA disease pathogenesis. Hence, this work predicts that muscle-directed therapies hold great promise as definitive treatments for SBMA motor neuron degeneration.</div></li><li class="half_rhythm"><div>Another study sought to ameliorate toxicity in mouse models of SBMA by suppressing polyQ-AR expression using antisense oligonucleotides (ASOs) [<a class="bk_pop" href="#kennedy.REF.lieberman.2014.774">Lieberman et al 2014</a>]. This investigation developed compounds to specifically target <i>AR</i> expression in the periphery, and using two mouse models, found that peripheral <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> suppression of mutated AR rescues deficits in muscle weight, fiber size, and grip strength; reverses changes in muscle gene expression; and extends the life span of mutated males. Interestingly, delivery of an anti-AR ASO to the CNS also elicited a modest improvement in these disease read-outs in a SBMA mouse model, but was much less effective than peripheral delivery. Hence, this report, together with the genetic rescue study of SBMA [<a class="bk_pop" href="#kennedy.REF.cortes.2014.295">Cortes et al 2014</a>], strongly suggests that peripheral administration of therapies directed to muscle should be explored in humans with SBMA. Preparations are underway to initiate a clinical trial of anti-AR ASO therapy via peripheral delivery in males with SBMA.</div></li></ul><p>Search <a href="http://clinicaltrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div><div id="kennedy.Other"><h3>Other</h3><p>Administration of male hormones (testosterone and its analogs) is not effective in overcoming the androgen insensitivity.</p></div></div><div id="kennedy.Genetic_Counseling"><h2 id="_kennedy_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="kennedy.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Spinal and bulbar muscular atrophy (SBMA) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p></div><div id="kennedy.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have the disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for a pathogenic CAG trinucleotide expansion in <i>AR</i>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div>To date, all mothers of men with SBMA who have been tested have been shown to carry one <i>AR</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> with an abnormal number of CAG repeats. However, SBMA is a late-onset disorder and mothers may not always be available for testing.</div></li><li class="half_rhythm"><div>The true incidence of <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> CAG trinucleotide expansion in men with SBMA is not presently known; no <i>de novo</i> expansions have been observed thus far.</div></li></ul><p><b>Sibs of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to sibs depends on the genetic status of the mother.</div></li><li class="half_rhythm"><div>Based on the observation that all tested mothers of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males are heterozygotes (carriers), the chance of transmitting the pathogenic CAG trinucleotide expansion in each pregnancy is 50%.</div></li><li class="half_rhythm"><div>Male sibs who inherit the pathogenic CAG trinucleotide expansion will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; female sibs who inherit the expansion will be heterozygotes (carriers) and will usually not be affected.</div></li></ul><p><b>Offspring of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Affected males transmit the pathogenic CAG trinucleotide expansion to:</p><ul><li class="half_rhythm"><div>All of their daughters who will be heterozygotes (carriers) and will usually not be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>;</div></li><li class="half_rhythm"><div>None of their sons.</div></li></ul><p><b>Other family members.</b> The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal aunts may be at risk of being heterozygotes (carriers) for the pathogenic CAG trinucleotide expansion and the aunt's offspring, depending on their gender, may be at risk of being carriers or of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p></div><div id="kennedy.Heterozygote_Carrier_Detection"><h3>Heterozygote (Carrier) Detection</h3><p>Once the <i>AR</i> CAG repeat expansion has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> of at-risk female relatives is possible.</p><p>Note: Females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (carriers) for this <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disorder will usually not be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p></div><div id="kennedy.Related_Genetic_Counseling_Issue"><h3>Related Genetic Counseling Issues</h3><p><b>CAG repeat instability.</b> Pathogenic <i>AR</i> alleles with abnormally large numbers of CAG repeats have the property of genetic instability, meaning that the number of CAG repeats often changes when transmitted from parent to offspring. In SBMA, a slight tendency toward expansion (an increase in number) of CAG repeats exists, although the number of CAG repeats is relatively stable with only small increases in repeat length and frequent small decreases in repeat number (i.e., contractions). Repeat instability with male transmission of a pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> has been described. Although a correlation exists between CAG repeat number and disease onset and severity in individuals with SBMA, prediction of disease course <b>cannot</b> be based on measured CAG repeat number.</p><p><b>Testing of at-risk asymptomatic adult relatives</b> of individuals with SBMA is possible after <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has identified a pathogenic CAG trinucleotide expansion in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member. Such testing is not useful in accurately predicting age of onset, severity, type of symptoms, or rate of disease progression in asymptomatic individuals.</p><p><b>Molecular genetic testing of asymptomatic individuals younger than age 18 years</b> who are at risk for adult-onset disorders for which no treatment exists is not considered appropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</p><p>It is appropriate to consider testing symptomatic individuals regardless of age in a family with an established diagnosis of SBMA.</p><p>For more information, see also the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="kennedy.Prenatal_Testing_and_Preimplanta"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once a pathogenic CAG trinucleotide expansion in <i>AR</i> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for SBMA are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="kennedy.Resources"><h2 id="_kennedy_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Kennedy's Disease Association, Inc.</b></div><div>PO Box 1105</div><div>Coarsegold CA 93614-1105</div><div><b>Phone:</b> 559-658-5950</div><div><b>Email:</b> info@kennedysdisease.org</div><div><a href="http://www.kennedysdisease.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.kennedysdisease.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=spinalandbulbarmuscularatrophy" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Spinal and bulbar muscular atrophy</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy Association - USA (MDA)</b></div><div>222 South Riverside Plaza</div><div>Suite 1500</div><div>Chicago IL 60606</div><div><b>Phone:</b> 800-572-1717</div><div><b>Email:</b> mda@mdausa.org</div><div><a href="http://www.mda.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mda.org</a></div></li></ul></div><div id="kennedy.Molecular_Genetics"><h2 id="_kennedy_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="kennedy.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Spinal and Bulbar Muscular Atrophy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1333/table/kennedy.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__kennedy.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_kennedy.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_kennedy.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_kennedy.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_kennedy.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_kennedy.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_kennedy.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_kennedy.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/367" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>AR</i></a></td><td headers="hd_b_kennedy.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=367" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq12</a></td><td headers="hd_b_kennedy.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P10275" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Androgen receptor</a></td><td headers="hd_b_kennedy.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/AR" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AR @ LOVD</a><br /><a href="http://alsod.iop.kcl.ac.uk/Als/Overview/gene.aspx?gene_id=AR" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">alsod/AR genetic mutations</a><br /><a href="http://androgendb.mcgill.ca/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">The Androgen Receptor Gene Mutations Database</a></td><td headers="hd_b_kennedy.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=AR" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AR</a></td><td headers="hd_b_kennedy.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=AR[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AR</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="kennedy.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="kennedy.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Spinal and Bulbar Muscular Atrophy (<a href="/omim/313200,313700" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1333/table/kennedy.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__kennedy.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/313200" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">313200</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPINAL AND BULBAR MUSCULAR ATROPHY, X-LINKED 1; SMAX1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/313700" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">313700</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ANDROGEN RECEPTOR; AR</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>AR</i> comprises eight exons and spans 180 kb [UCSC Genome Browser]. The longest transcript variant <a href="/nuccore/NM_000044.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000044.3</a> has 10,661 bp with a <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> of 2,763 bp. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1333/#kennedy.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> A highly polymorphic CAG repeat starting at amino acid codon number 58 is found within the AR coding <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>. Unaffected individuals have five to 34 CAG trinucleotide repeats; some may have reduced-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> alleles with 36-37 repeats (see <a href="#kennedy.Establishing_the_Diagnosis">Establishing the Diagnosis</a>).</p><p>About 98% of females are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> and have <i>AR</i> alleles with different numbers of CAG repeats on their two X chromosomes. The most common alleles number from 18 to 25 CAG repeats. Variation in mean CAG repeat length occurs within different racial populations, with Africans having the smallest mean CAG repeat length and Asians having the largest mean CAG repeat length; the CAG repeat length in white European populations is intermediate to these two.</p><p>The high degree of heterozygosity in females makes the <i>AR</i> CAG repeat a useful marker for studying <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>.</p><p><b>Pathogenic variants.</b> Expansion beyond the normal range of CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> within the <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> of <i>AR</i> causes the spinal bulbar muscular atrophy (SBMA) <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#kennedy.REF.la_spada.1991.77">La Spada et al 1991</a>].</p><p>Genetic testing of sperm of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male showed that 20% of the sperm had a CAG repeat number equal to that in the DNA from somatic cells, whereas 56% had further expansion of the CAG repeat number, and 24% had contraction of the CAG repeat number. Most of the allelic expansions and contractions were between one and three CAG repeats. Similar studies on oocytes have not been possible.</p><div id="kennedy.T.selected_ar_variants" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>AR</i> Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1333/table/kennedy.T.selected_ar_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__kennedy.T.selected_ar_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_kennedy.T.selected_ar_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_kennedy.T.selected_ar_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_kennedy.T.selected_ar_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_kennedy.T.selected_ar_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_kennedy.T.selected_ar_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_kennedy.T.selected_ar_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.172_174CAG(7_34)<br />(CAG ?-34 repeats)</td><td headers="hd_h_kennedy.T.selected_ar_variants_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;">See footnote&#x000a0;1</td><td headers="hd_h_kennedy.T.selected_ar_variants_1_1_1_4" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000044.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000044<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_000035.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000035<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_kennedy.T.selected_ar_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Unknown</b></td><td headers="hd_h_kennedy.T.selected_ar_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.172_174CAG(35)<br />(CAG 35 repeats)</td></tr><tr><td headers="hd_h_kennedy.T.selected_ar_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Reduced-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></b></td><td headers="hd_h_kennedy.T.selected_ar_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.172_174CAG(36_37)<br />(CAG 36-37 repeats)</td></tr><tr><td headers="hd_h_kennedy.T.selected_ar_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_kennedy.T.selected_ar_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.172_174CAG(38_68)<br />(CAG 38-? repeats)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="kennedy.TF.2.1"><p class="no_margin">Each CAG repeat results in the addition of a glutamine residue to the polymorphic polyglutamine repeat.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>AR</i> is a member of the steroid receptor superfamily and therefore displays a typical protein structure, consisting of a highly conserved DNA-binding <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> at the center of the protein and a highly conserved ligand-binding domain at the C-terminal end. <i>AR</i> transcript <a href="/nuccore/NM_000044.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000044.3</a> encodes a 920-amino acid protein with molecular mass of approximately 110 kd. A second isoform of approximately 87 kd is found in most cell types and likely reflects translation initiation at p.Met188 of the full-length protein [<a class="bk_pop" href="#kennedy.REF.gao.1998.654">Gao &#x00026; McPhaul 1998</a>]. The N-terminal region of the androgen receptor (AR) protein is relatively poorly conserved and is thought to mediate transcriptional activation of target genes [<a class="bk_pop" href="#kennedy.REF.zhou.1995.208">Zhou et al 1995</a>]. The AR protein contains a nuclear localization signal (NLS) at amino acids 627-658.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> CAG encodes the amino acid glutamine, therefore, CAG expansions produce an AR protein with an abnormally long polyglutamine stretch at the N-terminal end [<a class="bk_pop" href="#kennedy.REF.la_spada.1991.77">La Spada et al 1991</a>]. This expanded polyglutamine tract presumably alters the conformation of the AR protein (or an N-terminal peptide fragment from the AR protein) resulting in neurodegeneration in SBMA via a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> mechanism. The AR protein is expressed in the brain, spinal cord, and muscle [<a class="bk_pop" href="#kennedy.REF.matsuura.1993.5">Matsuura et al 1993</a>, <a class="bk_pop" href="#kennedy.REF.ogata.1994.1274">Ogata et al 1994</a>].</p><p>SBMA and other CAG trinucleotide expansion diseases involving the central nervous system result from the abnormal glutamine expansion in the protein [<a class="bk_pop" href="#kennedy.REF.la_spada.2010.247">La Spada &#x00026; Taylor 2010</a>]. Genes associated with these so-called "polyglutamine tract expansion diseases" produce unrelated proteins. How polyglutamine tract expansion leads to neurodegeneration in SBMA and these other diseases is still unknown [<a class="bk_pop" href="#kennedy.REF.la_spada.2010.247">La Spada &#x00026; Taylor 2010</a>]. One possible pathogenic cascade posits that the polyglutamine tract region is proteolytically processed and a polyglutamine-containing peptide fragment is retained in the nucleus, where it forms neuronal intranuclear inclusions (NIIs) [<a class="bk_pop" href="#kennedy.REF.young.2009.1987">Young et al 2009</a>]. Once in the nucleus, polyglutamine-expanded AR peptide fragments may cause pathology by interfering with transcriptional coactivators such as the CREB-binding protein [<a class="bk_pop" href="#kennedy.REF.mccampbell.2000.2197">McCampbell et al 2000</a>, <a class="bk_pop" href="#kennedy.REF.sopher.2004.687">Sopher et al 2004</a>]. NIIs have been found in spinal cord sections from deceased individuals with SBMA [<a class="bk_pop" href="#kennedy.REF.li.1998.249">Li et al 1998</a>]. In addition to <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> polyglutamine proteotoxicity, recent research work has focused on the role of altered normal function in dictating cell type specificity in SBMA, and this work suggests that altered protein complex interactions between AR and its coactivators and corepressors may underlie disease pathogenesis [<a class="bk_pop" href="#kennedy.REF.nedelsky.2010.936">Nedelsky et al 2010</a>].</p><p><b>Cancer and benign tumors.</b> Dozens of epidemiologic and genetic association studies have examined a potential inverse relationship between AR CAG repeat length and the risk of developing prostate cancer. In 2013, a meta-analysis of published data up to that time concluded that "a shorter CAG repeat <a class="def" href="/books/n/gene/glossary/def-item/polymorphism/">polymorphism</a> may increase the risk of prostate cancer compared with the longer CAG repeat; in particular, the effect of shorter CAG repeats on the increased risk of prostate cancer was predominantly observed in Caucasians [<i>i.e., persons of northern European background</i> &#x02013;ED.] and Asians" [<a class="bk_pop" href="#kennedy.REF.sun.2013.1195">Sun &#x00026; Lee 2013</a>].</p></div><div id="kennedy.References"><h2 id="_kennedy_References_">References</h2><div id="kennedy.Published_Guidelines__Consensus"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF1">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 8-14-19 [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF2">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset conditions. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2018. Accessed 8-14-19</div></li></ul></div><div id="kennedy.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.adachi.2005.659">Adachi H, Katsuno M, Minamiyama M, Waza M, Sang C, Nakagomi Y, Kobayashi Y, Tanaka F, Doyu M, Inukai A, Yoshida M, Hashizume Y, Sobue G. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. <span><span class="ref-journal">Brain. </span>2005;<span class="ref-vol">128</span>:659–70.</span> [<a href="/pubmed/15659427" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15659427</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.amato.1993.791">Amato AA, Prior TW, Barohn RJ, Snyder P, Papp A, Mendell JR. Kennedy's disease: a clinicopathologic correlation with mutations in the androgen receptor gene. <span><span class="ref-journal">Neurology. </span>1993;<span class="ref-vol">43</span>:791–4.</span> [<a href="/pubmed/8469342" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8469342</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.antonini.2000.252">Antonini G, Gragnani F, Romaniello A, Pennisi EM, Morino S, Ceschin V, Santoro L, Cruccu G. Sensory involvement in spinal-bulbar muscular atrophy (Kennedy's disease). <span><span class="ref-journal">Muscle Nerve. </span>2000;<span class="ref-vol">23</span>:252–8.</span> [<a href="/pubmed/10639619" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10639619</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.atsuta.2006.1446">Atsuta N, Watanabe H, Ito M, Banno H, Suzuki K, Katsuno M, Tanaka F, Tamakoshi A, Sobue G. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. <span><span class="ref-journal">Brain. </span>2006;<span class="ref-vol">129</span>:1446–55.</span> [<a href="/pubmed/16621916" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16621916</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.banno.2009.140">Banno H, Katsuno M, Suzuki K, Takeuchi Y, Kawashima M, Suga N, Takamori M, Ito M, Nakamura T, Matsuo K, Yamada S, Oki Y, Adachi H, Minamiyama M, Waza M, Atsuta N, Watanabe H, Fujimoto Y, Nakashima T, Tanaka F, Doyu M, Sobue G. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. <span><span class="ref-journal">Ann Neurol. </span>2009;<span class="ref-vol">65</span>:140–50.</span> [<a href="/pubmed/19259967" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19259967</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.cortes.2014.295">Cortes CJ, Ling SC, Guo LT, Hung G, Tsunemi T, Ly L, Tokunaga S, Lopez E, Sopher BL, Bennett CF, Shelton GD, Cleveland DW, La Spada AR. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. <span><span class="ref-journal">Neuron. </span>2014;<span class="ref-vol">82</span>:295–307.</span> [<a href="/pmc/articles/PMC4096235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4096235</span></a>] [<a href="/pubmed/24742458" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24742458</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.doyu.1993.832">Doyu M, Sobue G, Mitsuma T, Uchida M, Iwase T, Takahashi A. Very late onset X-linked recessive bulbospinal neuronopathy: mild clinical features and a mild increase in the size of tandem CAG repeat in androgen receptor gene. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1993;<span class="ref-vol">56</span>:832–3.</span> [<a href="/pmc/articles/PMC1015073/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1015073</span></a>] [<a href="/pubmed/8331366" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8331366</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.doyu.1992.707">Doyu M, Sobue G, Mukai E, Kachi T, Yasuda T, Mitsuma T, Takahashi A. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. <span><span class="ref-journal">Ann Neurol. </span>1992;<span class="ref-vol">32</span>:707–10.</span> [<a href="/pubmed/1449253" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1449253</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.echanizlaguna.2005.1458">Echaniz-Laguna A, Rousso E, Anheim M, Coss&#x000e9;e M, Tranchant C. A family with early-onset and rapidly progressive X-linked spinal and bulbar muscular atrophy. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">64</span>:1458–60.</span> [<a href="/pubmed/15851746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15851746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.fern_ndezrhodes.2011.140">Fern&#x000e1;ndez-Rhodes LE, Kokkinis AD, White MJ, Watts CA, Auh S, Jeffries NO, Shrader JA, Lehky TJ, Li L, Ryder JE, Levy EW, Solomon BI, Harris-Love MO, La Pean A, Schindler AB, Chen C, Di Prospero NA, Fischbeck KH. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. <span><span class="ref-journal">Lancet Neurol. </span>2011;<span class="ref-vol">10</span>:140–7.</span> [<a href="/pmc/articles/PMC3056353/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3056353</span></a>] [<a href="/pubmed/21216197" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21216197</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.ferrante.1997.323">Ferrante MA, Wilbourn AJ. The characteristic electrodiagnostic features of Kennedy's disease. <span><span class="ref-journal">Muscle Nerve. </span>1997;<span class="ref-vol">20</span>:323–9.</span> [<a href="/pubmed/9052811" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9052811</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.fischbeck.2009.119">Fischbeck KH, Bryan WW. Anti-androgen treatment for spinal and bulbar muscular atrophy. <span><span class="ref-journal">Ann Neurol. </span>2009;<span class="ref-vol">65</span>:119–20.</span> [<a href="/pmc/articles/PMC4280995/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4280995</span></a>] [<a href="/pubmed/19259961" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19259961</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.fischbeck.2012.257">Fischbeck KH. Developing treatment for spinal and bulbar muscular atrophy. <span><span class="ref-journal">Prog Neurobiol. </span>2012;<span class="ref-vol">99</span>:257–61.</span> [<a href="/pmc/articles/PMC3460036/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3460036</span></a>] [<a href="/pubmed/22668795" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22668795</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.gao.1998.654">Gao T, McPhaul MJ. Functional activities of the A and B forms of the human androgen receptor in response to androgen receptor agonists and antagonists. <span><span class="ref-journal">Mol Endocrinol. </span>1998;<span class="ref-vol">12</span>:654–63.</span> [<a href="/pubmed/9605928" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9605928</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.goldenberg.1996.158">Goldenberg JN, Bradley WG. Testosterone therapy and the pathogenesis of Kennedy's disease (X-linked bulbospinal muscular atrophy). <span><span class="ref-journal">J Neurol Sci. </span>1996;<span class="ref-vol">135</span>:158–61.</span> [<a href="/pubmed/8867072" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8867072</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.grunseich.2014a.978">Grunseich C, Kats IR, Bott LC, Rinaldi C, Kokkinis A, Fox D, Chen KL, Schindler AB, Mankodi AK, Shrader JA, Schwartz DP, Lehky TJ, Liu CY, Fischbeck KH. Early onset and novel features in a spinal and bulbar muscular atrophy patient with a 68 CAG repeat. <span><span class="ref-journal">Neuromuscul Disord. </span>2014a;<span class="ref-vol">24</span>:978–81.</span> [<a href="/pmc/articles/PMC4252652/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4252652</span></a>] [<a href="/pubmed/25047668" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25047668</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.grunseich.2014b.6">Grunseich C, Rinaldi C, Fischbeck KH. Spinal and bulbar muscular atrophy: pathogenesis and clinical management. <span><span class="ref-journal">Oral Dis. </span>2014b;<span class="ref-vol">20</span>:6–9.</span> [<a href="/pmc/articles/PMC4284073/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4284073</span></a>] [<a href="/pubmed/23656576" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23656576</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.harding.1982.1012">Harding AE, Thomas PK, Baraitser M, Bradbury PG, Morgan-Hughes JA, Ponsford JR. X-linked recessive bulbospinal neuronopathy: a report of ten cases. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1982;<span class="ref-vol">45</span>:1012–9.</span> [<a href="/pmc/articles/PMC491638/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC491638</span></a>] [<a href="/pubmed/6890989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6890989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.igarashi.1992.2300">Igarashi S, Tanno Y, Onodera O, Yamazaki M, Sato S, Ishikawa A, Miyatani N, Nagashima M, Ishikawa Y, Sahashi K, et al.  Strong correlation between the number of CAG repeats in androgen receptor genes and the clinical onset of features of spinal and bulbar muscular atrophy. <span><span class="ref-journal">Neurology. </span>1992;<span class="ref-vol">42</span>:2300–2.</span> [<a href="/pubmed/1461383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1461383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.katsuno.2010.875">Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Yabe I, Sasaki H, Aoki M, Morita M, Nakano I, Kanai K, Ito S, Ishikawa K, Mizusawa H, Yamamoto T, Tsuji S, Hasegawa K, Shimohata T, Nishizawa M, Miyajima H, Kanda F, Watanabe Y, Nakashima K, Tsujino A, Yamashita T, Uchino M, Fujimoto Y, Tanaka F, Sobue G., Japan SBMA Interventional Trial for TAP-144-SR (JASMITT) study group.  Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. <span><span class="ref-journal">Lancet Neurol. </span>2010;<span class="ref-vol">9</span>:875–84.</span> [<a href="/pubmed/20691641" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20691641</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.kennedy.1968.671">Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. <span><span class="ref-journal">Neurology. </span>1968;<span class="ref-vol">18</span>:671–80.</span> [<a href="/pubmed/4233749" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4233749</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.kuhlenb_umer.2001.23">Kuhlenb&#x000e4;umer G, Kress W, Ringelstein EB, St&#x000f6;gbauer F. Thirty-seven CAG repeats in the androgen receptor gene in two healthy individuals. <span><span class="ref-journal">J Neurol. </span>2001;<span class="ref-vol">248</span>:23–6.</span> [<a href="/pubmed/11266016" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11266016</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.la_spada.1992.301">La Spada AR, Roling DB, Harding AE, Warner CL, Spiegel R, Hausmanowa-Petrusewicz I, Yee WC, Fischbeck KH. Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal and bulbar muscular atrophy. <span><span class="ref-journal">Nat Genet. </span>1992;<span class="ref-vol">2</span>:301–4.</span> [<a href="/pubmed/1303283" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1303283</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.la_spada.1991.77">La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. <span><span class="ref-journal">Nature. </span>1991;<span class="ref-vol">352</span>:77–9.</span> [<a href="/pubmed/2062380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2062380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.la_spada.2010.247">La Spada AR, Taylor JP. Repeat expansion disease: progress and puzzles in disease pathogenesis. <span><span class="ref-journal">Nat Rev Genet. </span>2010;<span class="ref-vol">11</span>:247–58.</span> [<a href="/pmc/articles/PMC4704680/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4704680</span></a>] [<a href="/pubmed/20177426" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20177426</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.lee.2005.57">Lee JH, Shin JH, Park KP, Kim IJ, Kim CM, Lim JG, Choi YC, Kim DS. Phenotypic variability in Kennedy's disease: implication of the early diagnostic features. <span><span class="ref-journal">Acta Neurol Scand. </span>2005;<span class="ref-vol">112</span>:57–63.</span> [<a href="/pubmed/15932358" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15932358</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.li.1998.249">Li M, Miwa S, Kobayashi Y, Merry DE, Yamamoto M, Tanaka F, Doyu M, Hashizume Y, Fischbeck KH, Sobue G. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. <span><span class="ref-journal">Ann Neurol. </span>1998;<span class="ref-vol">44</span>:249–54.</span> [<a href="/pubmed/9708548" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9708548</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.lieberman.2014.774">Lieberman AP, Yu Z, Murray S, Peralta R, Low A, Guo S, Yu XX, Cortes CJ, Bennett CF, Monia BP, La Spada AR, Hung G. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. <span><span class="ref-journal">Cell Rep. </span>2014;<span class="ref-vol">7</span>:774–84.</span> [<a href="/pmc/articles/PMC4356525/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4356525</span></a>] [<a href="/pubmed/24746732" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24746732</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.lund.2000.631">Lund A, Udd B, Juvonen V, Andersen PM, Cederquist K, Ronnevi LO, Sistonen P, S&#x000f6;rensen SA, Tranebjaerg L, Wallgren-Pettersson C, Savontaus ML. Founder effect in spinal and bulbar muscular atrophy (SBMA) in Scandinavia. <span><span class="ref-journal">Eur J Hum Genet. </span>2000;<span class="ref-vol">8</span>:631–6.</span> [<a href="/pubmed/10951525" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10951525</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.mariotti.2000.391">Mariotti C, Castellotti B, Pareyson D, Testa D, Eoli M, Antozzi C, Silani V, Marconi R, Tezzon F, Siciliano G, Marchini C, Gellera C, Donato SD. Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. <span><span class="ref-journal">Neuromuscul Disord. </span>2000;<span class="ref-vol">10</span>:391–7.</span> [<a href="/pubmed/10899444" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10899444</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.matsuura.1993.5">Matsuura T, Ogata A, Demura T, Moriwaka F, Tashiro K, Koyanagi T, Nagashima K. Identification of androgen receptor in the rat spinal motoneurons. Immunohistochemical and immunoblotting analyses with monoclonal antibody. <span><span class="ref-journal">Neurosci Lett. </span>1993;<span class="ref-vol">158</span>:5–8.</span> [<a href="/pubmed/8233073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8233073</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.mazzini.2001.139">Mazzini L, Balzarini C, Colombo R, Mora G, Pastore I, De Ambrogio R, Caligari M. Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. <span><span class="ref-journal">J Neurol Sci. </span>2001;<span class="ref-vol">191</span>:139–44.</span> [<a href="/pubmed/11677005" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11677005</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.mccampbell.2000.2197">McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, Walcott J, Merry D, Chai Y, Paulson H, Sobue G, Fischbeck KH. CREB-binding protein sequestration by expanded polyglutamine. <span><span class="ref-journal">Hum Mol Genet. </span>2000;<span class="ref-vol">9</span>:2197–202.</span> [<a href="/pubmed/10958659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10958659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.nagashima.1988.141">Nagashima T, Seko K, Hirose K, Mannen T, Yoshimura S, Arima R, Nagashima K, Morimatsu Y. Familial bulbo-spinal muscular atrophy associated with testicular atrophy and sensory neuropathy (Kennedy-Alter-Sung syndrome). Autopsy case report of two brothers. <span><span class="ref-journal">J Neurol Sci. </span>1988;<span class="ref-vol">87</span>:141–52.</span> [<a href="/pubmed/3210030" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3210030</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.nance.1997.881">Nance MA. Clinical aspects of CAG repeat diseases. <span><span class="ref-journal">Brain Pathol. </span>1997;<span class="ref-vol">7</span>:881–900.</span> [<a href="/pubmed/9217974" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9217974</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.nedelsky.2010.936">Nedelsky NB, Pennuto M, Smith RB, Palazzolo I, Moore J, Nie Z, Neale G, Taylor JP. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. <span><span class="ref-journal">Neuron. </span>2010;<span class="ref-vol">67</span>:936–52.</span> [<a href="/pmc/articles/PMC3514079/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3514079</span></a>] [<a href="/pubmed/20869592" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20869592</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.ogata.1994.1274">Ogata A, Matsuura T, Tashiro K, Moriwaka F, Demura T, Koyanagi T, Nagashima K. Expression of androgen receptor in X-linked spinal and bulbar muscular atrophy and amyotrophic lateral sclerosis. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1994;<span class="ref-vol">57</span>:1274–5.</span> [<a href="/pmc/articles/PMC485506/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC485506</span></a>] [<a href="/pubmed/7931399" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7931399</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.olney.1991.823">Olney RK, Aminoff MJ, So YT. Clinical and electrodiagnostic features of X-linked recessive bulbospinal neuronopathy. <span><span class="ref-journal">Neurology. </span>1991;<span class="ref-vol">41</span>:823–8.</span> [<a href="/pubmed/2046924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2046924</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.parboosingh.1997.568">Parboosingh JS, Figlewicz DA, Krizus A, Meininger V, Azad NA, Newman DS, Rouleau GA. Spinobulbar muscular atrophy can mimic ALS: the importance of genetic testing in male patients with atypical ALS. <span><span class="ref-journal">Neurology. </span>1997;<span class="ref-vol">49</span>:568–72.</span> [<a href="/pubmed/9270598" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9270598</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.rhodes.2009.3242">Rhodes LE, Freeman BK, Auh S, Kokkinis AD, La Pean A, Chen C, Lehky TJ, Shrader JA, Levy EW, Harris-Love M, Di Prospero NA, Fischbeck KH. Clinical features of spinal and bulbar muscular atrophy. <span><span class="ref-journal">Brain. </span>2009;<span class="ref-vol">132</span>:3242–51.</span> [<a href="/pmc/articles/PMC2792370/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2792370</span></a>] [<a href="/pubmed/19846582" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19846582</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.sinnreich.2004.378">Sinnreich M, Sorenson EJ, Klein CJ. Neurologic course, endocrine dysfunction and triplet repeat size in spinal bulbar muscular atrophy. <span><span class="ref-journal">Can J Neurol Sci. </span>2004;<span class="ref-vol">31</span>:378–82.</span> [<a href="/pubmed/15376484" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15376484</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.sobue.1993.74">Sobue G, Doyu M, Kachi T, Yasuda T, Mukai E, Kumagai T, Mitsuma T. Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. <span><span class="ref-journal">J Neurol Sci. </span>1993;<span class="ref-vol">117</span>:74–8.</span> [<a href="/pubmed/8410070" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8410070</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.sopher.2004.687">Sopher BL, Thomas PS Jr, LaFevre-Bernt MA, Holm IE, Wilke SA, Ware CB, Jin LW, Libby RT, Ellerby LM, La Spada AR. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. <span><span class="ref-journal">Neuron. </span>2004;<span class="ref-vol">41</span>:687–99.</span> [<a href="/pubmed/15003169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15003169</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.sorar_.2008.100">Sorar&#x000f9; G, D'Ascenzo C, Polo A, Palmieri A, Baggio L, Vergani L, Gellera C, Moretto G, Pegoraro E, Angelini C. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. <span><span class="ref-journal">J Neurol Sci. </span>2008;<span class="ref-vol">264</span>:100–5.</span> [<a href="/pubmed/17854832" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17854832</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.sperfeld.2002.1921">Sperfeld AD, Karitzky J, Brummer D, Schreiber H, H&#x000e4;ussler J, Ludolph AC, Hanemann CO. X-linked bulbospinal neuronopathy: Kennedy disease. <span><span class="ref-journal">Arch Neurol. </span>2002;<span class="ref-vol">59</span>:1921–6.</span> [<a href="/pubmed/12470181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12470181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.sun.2013.1195">Sun JH, Lee SA. Association between CAG repeat polymorphisms and the risk of prostate cancer: a meta-analysis by race, study design and the number of (CAG)n repeat polymorphisms. <span><span class="ref-journal">Int J Mol Med. </span>2013;<span class="ref-vol">32</span>:1195–203.</span> [<a href="/pubmed/23982466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23982466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.tanaka.1996.1253">Tanaka F, Doyu M, Ito Y, Matsumoto M, Mitsuma T, Abe K, Aoki M, Itoyama Y, Fischbeck KH, Sobue G. Founder effect in spinal and bulbar muscular atrophy (SBMA). <span><span class="ref-journal">Hum Mol Genet. </span>1996;<span class="ref-vol">5</span>:1253–7.</span> [<a href="/pubmed/8872464" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8872464</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.warner.1992.2181">Warner CL, Griffin JE, Wilson JD, Jacobs LD, Murray KR, Fischbeck KH, Dickoff D, Griggs RC. X-linked spinomuscular atrophy: a kindred with associated abnormal androgen receptor binding. <span><span class="ref-journal">Neurology. </span>1992;<span class="ref-vol">42</span>:2181–4.</span> [<a href="/pubmed/1436532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1436532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.young.2009.1987">Young JE, Garden GA, Martinez RA, Tanaka F, Sandoval CM, Smith AC, Sopher BL, Lin A, Fischbeck KH, Ellerby LM, Morrison RS, Taylor JP, La Spada AR. Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk. <span><span class="ref-journal">J Neurosci. </span>2009;<span class="ref-vol">29</span>:1987–97.</span> [<a href="/pmc/articles/PMC2746676/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2746676</span></a>] [<a href="/pubmed/19228953" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19228953</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.zerres.1989.85">Zerres K. Classification and genetics of proximal spinal muscular atrophies. <span><span class="ref-journal">Prog Clin Biol Res. </span>1989;<span class="ref-vol">306</span>:85–9.</span> [<a href="/pubmed/2662215" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2662215</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="kennedy.REF.zhou.1995.208">Zhou ZX, Lane MV, Kemppainen JA, French FS, Wilson EM. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. <span><span class="ref-journal">Mol Endocrinol. </span>1995;<span class="ref-vol">9</span>:208–18.</span> [<a href="/pubmed/7776971" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7776971</span></a>]</div></li></ul></div></div><div id="kennedy.Chapter_Notes"><h2 id="_kennedy_Chapter_Notes_">Chapter Notes</h2><div id="kennedy.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>26 January 2017 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 July 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>13 October 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>28 December 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 July 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>29 August 2002 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 February 1999 (pb) Review posted live</div></li><li class="half_rhythm"><div>15 December 1998 (als) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1333</span><span class="label">PMID: <a href="/pubmed/20301508" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301508</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/spg11/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sma/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1333&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1333/?report=reader">PubReader</a></li><li><a href="/books/NBK1333/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1333" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1333" style="display:none" title="Cite this Page"><div class="bk_tt">La Spada A. Spinal and Bulbar Muscular Atrophy. 1999 Feb 26 [Updated 2017 Jan 26]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1333/pdf/Bookshelf_NBK1333.pdf">PDF version of this page</a> (444K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#kennedy.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#kennedy.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#kennedy.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#kennedy.Genetically_Related_Allelic_Diso" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#kennedy.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#kennedy.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#kennedy.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#kennedy.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#kennedy.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#kennedy.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#kennedy.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=367[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">AR</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1462258" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1462258" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1462258" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1462258" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/16772330" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy.</a><span class="source">[Hum Mol Genet. 2006]</span><div class="brieflinkpop offscreen_noflow">Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Thomas PS Jr, Fraley GS, Damian V, Woodke LB, Zapata F, Sopher BL, Plymate SR, La Spada AR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Hum Mol Genet. 2006 Jul 15; 15(14):2225-38. Epub 2006 Jun 13.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30006721" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Kennedy's disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease.</a><span class="source">[J Neurol. 2019]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Kennedy's disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Breza M, Koutsis G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Neurol. 2019 Mar; 266(3):565-573. Epub 2018 Jul 13.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25047668" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Early onset and novel features in a spinal and bulbar muscular atrophy patient with a 68 CAG repeat.</a><span class="source">[Neuromuscul Disord. 2014]</span><div class="brieflinkpop offscreen_noflow">Early onset and novel features in a spinal and bulbar muscular atrophy patient with a 68 CAG repeat.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Grunseich C, Kats IR, Bott LC, Rinaldi C, Kokkinis A, Fox D, Chen KL, Schindler AB, Mankodi AK, Shrader JA, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Neuromuscul Disord. 2014 Nov; 24(11):978-81. Epub 2014 Jul 3.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/8867071" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Spinal and bulbar muscular atrophy: androgen receptor dysfunction caused by a trinucleotide repeat expansion.</a><span class="source">[J Neurol Sci. 1996]</span><div class="brieflinkpop offscreen_noflow">Spinal and bulbar muscular atrophy: androgen receptor dysfunction caused by a trinucleotide repeat expansion.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">MacLean HE, Warne GL, Zajac JD. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Neurol Sci. 1996 Feb; 135(2):149-57. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23656576" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinal and bulbar muscular atrophy: pathogenesis and clinical management.</a><span class="source">[Oral Dis. 2014]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinal and bulbar muscular atrophy: pathogenesis and clinical management.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Grunseich C, Rinaldi C, Fischbeck KH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Oral Dis. 2014 Jan; 20(1):6-9. Epub 2013 May 9.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301508" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301508" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040db2dd21425a255f8922">Spinal and Bulbar Muscular Atrophy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Spinal and Bulbar Muscular Atrophy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:32:34-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8C95E7E040AE210000000001230069&amp;ncbi_session=CE8C95E7E040DB11_0291SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1333%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1333&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1333/&amp;ncbi_pagename=Spinal and Bulbar Muscular Atrophy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C95E7E040DB11_0291SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>